02 October 2025   Microvessels - capillaries and post‑capillary venules - are the smallest vessels in the circulation, with a cellular composition and thin-walled structure that enables nutrient exchange, oxygen delivery, waste removal, and immune‑cell trafficking between the blood and surrounding tissue cells. The absence of microvascular function is often cited as a major bottleneck of in vitro preclinical models, leading to tissue necrosis and limiting physiological releva

10 February 2026   European pioneers of human-based microphysiological systems (MPS) announce  the launch of of IAMPS – the Industry Alliance for Microphysiological Systems, dedicated to advancing MPS technologies. This alliance was formed by leading innovators in next gen human biology platforms  – AlveoliX (Switzerland), BiomimX (Italy), chiron (Netherlands), Dynamic42 (Germany), InSphero (Switzerland), MIMETAS (Netherlands), NETRI (France), React4Life (Italy), and TissUse

17 December 2025   Hesperos announces the establishment of a strategic channel sales and marketing partnership with AsedaSciences, offering its pharmaceutical, cosmetic, nutraceutical and chemical industry clients a powerful combination of human-based, in silico and in vitro tools for development of safer compounds.   Traditionally, compound safety has been assessed using animal testing, but these models raise ethical concerns, lack human physiological relevance, and offer l

17 October 2025   Hesperos Inc. has been awarded  a Phase IIB SBIR grant from the National Institute on Aging to investigate the effects of medication on cognitive impairment.   In humans, drug-induced cognitive decline may arise from subtle network‑level disruption, synaptic dysfunction, neurotransmitter imbalance and moderate neuroinflammation. However, these effects are very challenging to detect using standard in vitro models and animal testing. Cognitive decline is typic

25 September 2025   Cedars-Sinai Medical Center based in Los Angeles has been awarded $5M by Advanced Research Projects Agency for Health (ARPA-H) to develop a human-based AI-driven KronosRx platform  for improved prediction of adverse drug effects.   The ARPA-H Computational ADME-Tox and Physiology Analysis for Safer Therapeutics ( CATALYST ) program aims to revolutionize preclinical drug safety prediction by facilitating the development of next gen in vitro and in silico mo

14 October 2025   Cambridge-based CN Bio , a leading provider of organ-on-a-chip solutions, today announced  the launch of its PhysioMimix ®  Core  microphysiological system. The idea behind this product development was to merge the existing PhysioMimix single-organ, multi-organ and higher throughput systems into one intuitive, adaptable and universal organ-on-a-chip platform so that researchers could use it with maximum flexibility.   Compact and scalable, this latest CN Bio

30 June 2025   The Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to riliprubart for treating chronic inflammatory demyelinating polyneuropathy (CIDP), Sanofi reports . Riliprubart also holds this designation for CIDP in the EU and US.   By engineering a human-relevant chronic inflammatory demyelinating polyneuropathy-on-chip as a preclinical tool for disease modelling and drug efficacy testing, Hesperos has played an instrumental role in

27 October 2025   As we enter a new era of drug discovery, where IND authorization can now be granted based on human data only, marking a clean departure from mandatory animal testing, Qureator's human organ-on-chip platform has laid the groundwork for the world’s first IND approval of its kind .   The IND grant concerns SillaJen's BAL0891-tislelizumab combination therapy to treat solid tumors. Qureator's patient-derived vascularized tumor immune microenvironment (TME) model

16 December 2025   Put in place to accelerate the development of innovative cancer therapies through collaboration initiatives, the Netherlands-based Oncode Accelerator program announces launching of its Demonstrator Project. Through this project, researchers and drug developers will be able to share expertise, experimental platforms, and infrastructure to advance novel therapeutic approaches.   Recent advances in cancer therapies and in particular immunotherapy have produce

26 September 2025   Inductive Bio , an AI drug discovery partner developing virtual chemistry labs, is awarded up to $21M by Advanced Research Projects Agency for Health (ARPA-H)  to develop AI-powered human-relevant drug toxicity prediction models. ARPA-H Computational ADME-Tox and Physiology Analysis for Safer Therapeutics  (CATALYST) program aims to revolutionize preclinical drug safety prediction by leveraging human-based models that assess safety of drug candidates more

18 November 2025   Emulate, Inc.  the pioneer of organ-on-a-chip technology, announces the launch of its Brain-Chip R1 platform, marketed as a first-in-class comprehensive model of the neurovascular unit. This latest organ-on-chip model provides the means for human-relevant drug discovery, assessment of drug transport across the blood-brain barrier (BBB), and investigation of mechanisms of neuroinflammation.   This is particularly important since human neurological diseases,